Results 71 to 80 of about 91,755 (270)
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi +2 more
wiley +1 more source
Background The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy.
Takaaki Arigami +10 more
doaj +1 more source
Objectives: Present the case of a 67-year-old male with stage IV malignant melanoma who presented with uveitis and sensorineural hearing loss (SNHL) while on nivolumab and review the literature for likely etiologies.
Alex J. F. Tampio MD +3 more
doaj +1 more source
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley +1 more source
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Background Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs).
Vivek Verma +6 more
doaj +1 more source
Genital lichen sclerosus after nivolumab [PDF]
We report a patient with metastatic melanoma undergoing treatment with nivolumab who developed genital lichen sclerosus.
Soda, Giuseppe +6 more
core +1 more source
Background Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 protein and has been approved for the treatment of multiple advanced malignancies.
Shagufta Shaheen +3 more
doaj +1 more source
A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis
Nivolumab (Opdivo) approval for the treatment of non-small cell lung cancer (NSCLC) prompts recognition of its future use in various cancers. Although rare, occurring in 1% to 3% of treated cases, nivolumab along with other immune checkpoint inhibitors ...
Sowmya Nanjappa +3 more
core +1 more source
ABSTRACT Background H&N Merkel cell carcinoma (MCC) mainly affects elderly patients, yet age‐stratified treatment patterns and outcomes data are scarce. Methods We analyzed 88 consecutive H&N MCC patients (2000–2022) by age (< 75 vs. ≥ 75 years). OS was estimated by Kaplan–Meier analysis and MCC‐specific death with competing‐risks methods (cause ...
Igor Vainer +3 more
wiley +1 more source
Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Khanal S, Zhang H
doaj

